type here...

CATEGORIES

Medication

LATEST

1234Page 3 of 4

TRENDING

EDITORS CHOICE

Is the New York Times a Shill for Promoters of Psychedelics?

James Coyne -
Evidence that the newspaper is not sufficiently detached from promoters to provide an open-minded but skeptical perspective that readers should be able to expect.

The Trauma of Witnessing Charlie Kirk’s Murder and PTSD

Pat Farrell PhD -
The psychological effects of public space shootings extend beyond physical harm because they create a broad psychological impact on everyone present at the scene....

FDA Approval of New Drug for Alzheimer’s Offers Hope

Dr Jeff Livingston -
The FDA approves Aduhelm for the treatment of early Alzheimer's disease. Aduhelm targets brain plaque formation to slow the rate of cognitive decline.

2024 Health Trends: Progress, Challenges, and Opportunities

Gil Bashe, Medika Life Editor -
Here are 10 health-sector developments—not ranked—to watch in the coming year, determined by media coverage, reader interest, and personal interest.

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

© Medika Life 2020 - 2022

Compliance

CORPORATE & MEDIA

Popular categories